Drug · Other
Peginterferon Alfa-2b
CI-DRUG-00000463Explore in graph →NCIt C1845 CHEMBL1201561 CIViC Approved
Regulatory
Approvals (17)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as VICTRELIS TRIPLE (DIN 02371448) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Jan 10, 2017 | Aug 16, 2011 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as VICTRELIS TRIPLE (DIN 02371464) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Sep 2, 2016 | Aug 16, 2011 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as VICTRELIS TRIPLE (DIN 02371472) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawn |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 16 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Withdrawn | Phase 4 | 3 | 1 | 8 | 50 | 17 | CA | — | Dec 29, 1997 |
| Malignant Liver Neoplasm | Phase3 | Phase 3 | 1 | 0 | 1 | 2 | 0 | — | — | 2002-03 |
| Leukemia | Phase3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | Oct 22, 1998 |
| Malignant Kidney Neoplasm | Phase2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — |
Curated evidence
Clinical evidence (1)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 16709929
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| JAK2 V617F1 | ||||||||
| Peginterferon Alfa-2b | Polycythemia Vera | |||||||
Clinical trials
Trials with this intervention (50)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00539591 | Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma | active not recruiting | Phase 2 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07553767 | Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection |